#ANRO

StockTitan

@stocktitan.net

2 days ago

Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum Alto Neuroscience (NYSE: ANRO) said members of management will present in a virtual fireside chat at the Stifel 2026 Virtual CNS Forum on March 17, 2026 at 12:00pm ET.The presentation will stream live via a webcast on Alto's Investors Events and Presentations page, and a replay will be available after the event.

#ANRO Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum

www.stocktitan.net/news/ANRO/alto-neuroscie...

PRISM MarketView

@prismmarketview.bsky.social

2 months ago

A somber visual representing the emotional and clinical burden of depression, aligning with Alto Neuroscience’s continued progress in advancing innovative neuroscience therapies through expanded patent protection for ALTO-207.

Alto Neuroscience (NYSE: #ANRO) has secured a new U.S. patent for using its ALTO‑207 combo of pramipexole and ondansetron to treat depression, extending IP protection into the mid‑2040s.
prismmarketview.com/alto-neurosc...

StockTitan

@stocktitan.net

2 months ago

Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression Alto Neuroscience (NYSE: ANRO) announced the issuance of U.S. Patent No. 12,521,374 on January 14, 2026, covering methods of treating depression with ALTO-207, a combination of pramipexole and ondansetron. The patent specifically claims the use of ondansetron to mitigate pramipexole-related side effects, enabling higher pramipexole dose levels to achieve antidepressant effects. The company says issued and pending claims for ALTO-207, in the U.S. and internationally, are expected to provide protection into the mid-2040s, which it says strengthens the long-term commercial opportunity for the program.

#ANRO Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression

www.stocktitan.net/news/ANRO/alto-neuroscie...

Shortfinder

@shortfinder.bsky.social

2 months ago

ANRO Faces Acute Supply Risk as PIPE Shares Enter the Market Our machine learning model identifies ANRO as the highest-risk stock in our universe. The model assigns a 54.2% probability that ANRO declines more than one standard deviation over the next five tradi...

www.shortfinder.com/anro-faces-a... #ANRO #stocks #shortselling

Market Wire News

@marketwirenews.com

3 months ago

News; ( NYSE: #ANRO ) Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08

StockTitan

@stocktitan.net

4 months ago

Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights Alto Neuroscience, Inc. a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the quarter ended September 30, 2025, and highlighted recent progress across its pipeline of clinical-stage product candidates. “These past months marked a...

#ANRO Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights

www.stocktitan.net/news/ANRO/alto-neuroscie...

Market Wire News

@marketwirenews.com

4 months ago

Just In: ( NYSE: #ANRO ) NYSE Content Advisory: Pre-Market Update + Government Shutdown Nears End After 42 Days

Small Cap Strategist

@smcapstrategist.bsky.social

4 months ago

Most searched small-cap stocks, Mon Oct 20th - #UAMY #RR #NUAI #LAES #ANRO #AREC #RXRX #GSIT #GGB #WRD #USAR #REPL #RAMP #PTEN #QSI #NVTS #LUNR #IDR #BYND #BBAI - More: crystalequityresearch.com/most-searche... - #smallcap

StockTitan

@stocktitan.net

4 months ago

Alto Neuroscience Announces $50 Million Private Placement Financing Alto Neuroscience (NYSE: ANRO) entered a private placement (PIPE) to raise approximately $50 million in gross proceeds, led by Perceptive Advisors with participation from several biotech investors.Alto is selling 3,832,263 common shares at $5.914 per share and issuing pre-funded warrants to buy up to 4,622,251 shares at $5.9139 each (exercise price $0.0001). The PIPE is expected to close on October 21, 2025 and was priced at-the-market under NYSE rules.Proceeds are earmarked to accelerate development of ALTO-207 for treatment resistant depression after a successful FDA meeting; Alto expects to start a Phase 2b by mid-2026 and now also expects to initiate a Phase 3 by early 2027.

#ANRO Alto Neuroscience Announces $50 Million Private Placement Financing

www.stocktitan.net/news/ANRO/alto-neuroscie...

StockTitan

@stocktitan.net

4 months ago

Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting Alto Neuroscience, Inc., a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, announced today that, following a successful outcome from a recent FDA meeting, it plans to accelerate the development of ALTO-207 for people with treatment resistant depression.

#ANRO Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting

www.stocktitan.net/news/ANRO/alto-neuroscie...

StockTitan

@stocktitan.net

5 months ago

Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia Alto Neuroscience (NYSE: ANRO) announced on October 3, 2025 that the U.S. FDA granted Fast Track designation to ALTO-101 for the treatment of cognitive impairment associated with schizophrenia (CIAS). ALTO-101 is a novel PDE4 inhibitor that increased cAMP and showed pro‑cognitive effects in healthy volunteers in Phase 1, with significant effects on EEG measures and cognitive performance. Enrollment is ongoing in a Phase 2 proof-of-concept study in patients with CIAS. Fast Track status may enable more frequent FDA interactions and potential eligibility for accelerated approval or priority review if criteria are met.

#ANRO Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia

www.stocktitan.net/news/ANRO/alto-neuroscie...

Thiard News@F4F

@newsen.bsky.social

5 months ago

Gross Law Firm Alerts Investors of Alto Neuroscience's Class Action Deadline on September 19, 2025 The Gross Law Firm is reminding Alto Neuroscience investors of a pending class action lawsuit with a crucial lead plaintiff deadline looming on September 19, 2025.

Gross Law Firm Alerts Investors of Alto Neuroscience's Class Action Deadline on September 19, 2025 #United_States #New_York #Class_Action #Alto_Neuroscience #ANRO

Thiard News@F4F

@newsen.bsky.social

5 months ago

Alto Neuroscience Faces Class Action Lawsuit for Securities Violations Alto Neuroscience, Inc. is facing a class action lawsuit for allegedly violating securities laws, as investors are urged to come forward for potential recovery.

Alto Neuroscience Faces Class Action Lawsuit for Securities Violations #USA #Los_Angeles #DJS_Law_Group #Alto_Neuroscience #ANRO

Thiard News@F4F

@newsen.bsky.social

5 months ago

Investors Invited to Lead Class Action Against Alto Neuroscience for Securities Fraud The Schall Law Firm has initiated a class action lawsuit against Alto Neuroscience, Inc., inviting investors to participate in seeking justice for misleading securities practices.

Investors Invited to Lead Class Action Against Alto Neuroscience for Securities Fraud #United_States #Los_Angeles #Schall_Law_Firm #Alto_Neuroscience #ANRO

Thiard News@F4F

@newsen.bsky.social

6 months ago

Investors Provided Chance to Lead Securities Fraud Suit Against Alto Neuroscience, Inc. Rosen Law Firm reminds investors in Alto Neuroscience, Inc. of an impending chance to lead a securities fraud lawsuit with September 19 deadline.

Investors Provided Chance to Lead Securities Fraud Suit Against Alto Neuroscience, Inc. #United_States #New_York #Rosen_Law_Firm #Alto_Neuroscience #ANRO

StockTitan

@stocktitan.net

6 months ago

Alto Neuroscience Announces Robust Replication of EEG Biomarker to Objectively Identify Patients with Cognitive Impairment in Schizophrenia Alto Neuroscience (NYSE:ANRO) announced positive results from an independent replication study validating EEG biomarkers in schizophrenia patients. The study confirmed that theta-band inter-trial coherence (ITC) effectively distinguishes individuals with schizophrenia from healthy controls.The analysis, involving 155 schizophrenia patients and 272 healthy controls, demonstrated that theta ITC and event-related spectral perturbation (ERSP) showed the strongest case-control differences (Cohen's d = 0.64 and 0.78, respectively; p These findings support Alto's use of theta ITC as a primary outcome measure in their ongoing Phase 2 trial of ALTO-101, a PDE4 inhibitor being developed for cognitive impairment associated with schizophrenia (CIAS).

#ANRO Alto Neuroscience Announces Robust Replication of EEG Biomarker to Objectively Identify Patients with Cognitive Impairment in Schizophrenia

www.stocktitan.net/news/ANRO/alto-neuroscie...

Thiard News@F4F

@newsen.bsky.social

6 months ago

Alto Neuroscience Faces Class Action Lawsuit Over Securities Violations Alto Neuroscience, Inc. is under a class action lawsuit for alleged securities law violations, concerning misleading statements about its treatment efficacy.

Alto Neuroscience Faces Class Action Lawsuit Over Securities Violations #United_States #Los_Angeles #DJS_Law_Group #Alto_Neuroscience #ANRO

Thiard News@F4F

@newsen.bsky.social

6 months ago

Alto Neuroscience Faces Class Action Lawsuit Over Alleged Securities Violations: Key Deadlines for Investors Alto Neuroscience, Inc. is embroiled in a class action lawsuit related to securities fraud. Investors are encouraged to take action before the deadline on September 19, 2025.

Alto Neuroscience Faces Class Action Lawsuit Over Alleged Securities Violations: Key Deadlines for Investors #USA #New_York #Levi_Korsinsky #Alto_Neuroscience #ANRO

Thiard News@F4F

@newsen.bsky.social

6 months ago

Alto Neuroscience Faces Class Action Lawsuit for Securities Violations: Key Information for Investors Alto Neuroscience, Inc. is embroiled in a class action lawsuit due to alleged securities law violations. Investors eligible for recovery must act quickly.

Alto Neuroscience Faces Class Action Lawsuit for Securities Violations: Key Information for Investors #United_States #Los_Angeles #DJS_Law_Group #Alto_Neuroscience #ANRO

Thiard News@F4F

@newsen.bsky.social

6 months ago

Investors Urged to Join Alto Neuroscience Securities Class Action Lawsuit The Gross Law Firm informs Alto Neuroscience, Inc. shareholders of a lawsuit over securities law violations, encouraging participation in the class action.

Investors Urged to Join Alto Neuroscience Securities Class Action Lawsuit #United_States #New_York #Class_Action #Alto_Neuroscience #ANRO

Thiard News@F4F

@newsen.bsky.social

6 months ago

Alto Neuroscience Faces Legal Action Over Alleged Securities Law Violations Alto Neuroscience, Inc. is under legal scrutiny for alleged securities law violations. Shareholders are urged to connect with The Gross Law Firm for assistance.

Alto Neuroscience Faces Legal Action Over Alleged Securities Law Violations #United_States #New_York #Gross_Law_Firm #Alto_Neuroscience #ANRO

Thiard News@F4F

@newsen.bsky.social

6 months ago

Class Action Lawsuit Against Alto Neuroscience Seeks Investor Recovery Amid Allegations of Fraud Levi & Korsinsky, LLP has launched a class action lawsuit against Alto Neuroscience, Inc. to recover losses for investors affected by alleged securities fraud related to its product pipeline.

Class Action Lawsuit Against Alto Neuroscience Seeks Investor Recovery Amid Allegations of Fraud #USA #New_York #Levi_&_Korsinsky #Alto_Neuroscience #ANRO

Thiard News@F4F

@newsen.bsky.social

6 months ago

Lead Plaintiff Opportunities in Alto Neuroscience, Inc. Securities Fraud Lawsuit for ANRO Investors Alto Neuroscience, Inc. investors have a chance to be lead plaintiffs in a class action lawsuit for securities fraud impacting stock values after IPO.

Lead Plaintiff Opportunities in Alto Neuroscience, Inc. Securities Fraud Lawsuit for ANRO Investors #USA #New_York #Rosen_Law_Firm #Alto_Neuroscience #ANRO

Thiard News@F4F

@newsen.bsky.social

6 months ago

Important Notice for Alto Neuroscience Investors: Lead Plaintiff Deadline Approaches Soon A class action lawsuit against Alto Neuroscience has a lead plaintiff deadline looming on September 19, 2025. Know your rights as an investor.

Important Notice for Alto Neuroscience Investors: Lead Plaintiff Deadline Approaches Soon #USA #New_York #Levi_Korsinsky #Alto_Neuroscience #ANRO

Thiard News@F4F

@newsen.bsky.social

6 months ago

Attention Alto Neuroscience, Inc. Shareholders: Important Rights Notice from The Gross Law Firm Alto Neuroscience shareholders are urged to contact The Gross Law Firm before September 19, 2025, to discuss potential rights following false claims about their product.

Attention Alto Neuroscience, Inc. Shareholders: Important Rights Notice from The Gross Law Firm #United_States #New_York #Gross_Law_Firm #Alto_Neuroscience #ANRO

Thiard News@F4F

@newsen.bsky.social

6 months ago

Deadline Approaches for Alto Neuroscience Shareholders to Join Class Action Lawsuit Against ANRO Shareholders of Alto Neuroscience, Inc. should be aware of the lead plaintiff deadline for a class action lawsuit approaching on September 19, 2025.

Deadline Approaches for Alto Neuroscience Shareholders to Join Class Action Lawsuit Against ANRO #United_States #New_York #Gross_Law_Firm #Alto_Neuroscience #ANRO

StockTitan

@stocktitan.net

7 months ago

Alto Neuroscience Expands Depression Drug Pipeline, Secures Funding Through 2028 Mental health biotech acquires promising depression treatment ALTO-207, advances multiple late-stage trials. $148.1M cash supports operations through four clinical readouts. See pipeline details.

#ANRO Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights

www.stocktitan.net/news/ANRO/alto-neuroscie...

Thiard News@F4F

@newsen.bsky.social

7 months ago

Alto Neuroscience Faces Class Action Lawsuit Over Securities Violations Alto Neuroscience, Inc. is facing a class action lawsuit for alleged securities law violations. Investors affected by potential fraud should contact Levi & Korsinsky.

Alto Neuroscience Faces Class Action Lawsuit Over Securities Violations #United_States #New_York #Levi_&_Korsinsky #Alto_Neuroscience #ANRO